Update on emerging treatments for migraine / edited by Shuu-Jiun Wang, Chi Ieong Lau.

Other author Wang, Shuu-Jiun.
Other author Lau, Chi leong.
Format Electronic
EditionFirst edition.
Publication InfoAmsterdam : Elsevier, 2020.
Descriptionxxi, 418 pages : illustrations ; 24 cm.
Supplemental ContentFull text available from Book Series Package - Life Sciences [BSLFSC]
Subjects
Migraine--Treatment.
Migraine Disorders--therapy.
Migraine--Traitement.

SeriesProgress in brain research, 0079-6123 ; volume 255
Progress in brain research v. 255. 0079-6123 ^A75148
Contents Intro -- Update on Emerging Treatments for Migraine -- Copyright -- Contributors -- Contents -- Preface -- Chapter 1: Update in migraine preventive treatment -- Abstract -- Keywords -- 1. Introduction -- 2. Preventive medications for migraine -- 2.1. Beta-blockers -- 2.2. Antiepileptic drugs -- 2.3. Calcium channel blockers -- 2.4. Antidepressants -- 2.5. Non-steroid anti-inflammatory drugs (NSAIDs) -- 2.6. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) -- 2.7. Miscellaneous -- 3. Preventive medications for chronic migraine -- 3.1. OnabotulinumtoxinA
Contents 3.2. Topiramate -- 4. Calcitonin gene-related peptide monoclonal antibodies -- 4.1. Erenumab -- 4.2. Galcanezumab -- 4.3. Fremanezumab -- 4.4. Eptinezumab -- 5. Special considerations -- 5.1. Menstrual-related migraine -- 5.2. Pregnancy and breastfeeding -- 5.3. Children and adolescents -- 6. Conclusion -- References -- Chapter 2: Therapeutic implications of cortical spreading depression models in migraine -- Abstract -- Keyword -- 1. Migraine -- 2. Cortical spreading depression -- 3. Basics on in vivo experimental models of CSD -- 4. Consequences of CSD -- 4.1. Trigeminovascular activation
Contents 4.2. Cortical inflammation -- 4.3. Disruption of blood-brain barrier and impaired glymphatic flow -- 5. Migraine modulators affect CSD susceptibility -- 5.1. Genetic factors -- 5.2. Sex and age -- 5.3. Stress, sleep deprivation and hypoglycemia -- 6. CSD inhibition reflecting clinical responsiveness -- 7. CSD inhibitors that inhibit migraine aura but not headache -- 7.1. Ketamine -- 7.2. Lamotrigine -- 7.3. Tonabersat -- 8. Novel targets for migraine therapeutics -- 8.1. Calcitonin gene-related peptide -- 8.2. Ion channels -- 8.2.1. Pannexin-1 channels and P2X7 receptors
Contents 8.2.2. Acid-sensing ion channels (ASICs) -- 8.2.3. Transient receptor potential (TRP) channels -- 8.2.4. TWIK-related spinal cord potassium channel (TRESK) -- 8.3. Insulin-like growth factor-1 (IGF-1) -- 8.4. Neuromodulation -- 8.4.1. Vagus nerve stimulation -- 8.4.2. Transcranial magnetic stimulation -- 8.4.3. Transcranial direct current stimulation -- 9. Future directions and potentials for CSD models -- 10. Conclusion -- Funding -- References -- Chapter 3: Electrophysiological basis for antiepileptic drugs in migraine prevention -- Abstract -- Keywords -- 1. Introduction
Contents 2. Basic concepts of electrophysiological studies in migraine -- 3. The visual cortex -- 3.1. Steady-state visual evoked potential (SSVEP) -- 3.2. Pattern reversal visual evoked potential (PRVEP) -- 3.3. Phosphene induced by transcranial magnetic stimulation -- 3.4. Magnetic suppression of perceptual accuracy (MSPA) -- 4. The somatosensory cortex -- 4.1. Standard (broad-band) somatosensory evoked potential -- 4.2. High-frequency oscillations of the somatosensory evoked potential -- 5. The motor cortex -- 5.1. Motor threshold (MTh) and motor evoked potentials (MEPs) -- 5.2. Silent period (SP)
Bibliography noteIncludes bibliographical references.
Access restrictionAvailable only to authorized users.
Technical detailsMode of access: World Wide Web
Terms of useCurrent copyright fee: GBP32.84 5\1.
Issued in other formebook version : 9780128211090
Genre/formElectronic books.
LCCN 2022304161
ISBN0128211083
ISBN9780128211083
ISBNebook

Availability

Library Location Call Number Status Item Actions
Electronic Resources Access Content Online ✔ Available